Nothing Special   »   [go: up one dir, main page]

MX2019000529A - Proteina de suministro cerebral. - Google Patents

Proteina de suministro cerebral.

Info

Publication number
MX2019000529A
MX2019000529A MX2019000529A MX2019000529A MX2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A MX 2019000529 A MX2019000529 A MX 2019000529A
Authority
MX
Mexico
Prior art keywords
brain
brain delivery
protein
binding antibody
present
Prior art date
Application number
MX2019000529A
Other languages
English (en)
Inventor
Lannfelt Lars
Sehlin Dag
Hultqvist Greta
Syvänen Stina
Original Assignee
Bioarctic Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Ab filed Critical Bioarctic Ab
Publication of MX2019000529A publication Critical patent/MX2019000529A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70582—CD71

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una proteína de suministro cerebral, que comprende un anticuerpo de unión al objetivo que se une a un objetivo que se une a un objetivo en el cerebro de un mamífero; dos restos portadores, cada uno de los cuales es capaz de una interacción monovalente con una proteína expresada en una célula endotelial de la barrera hematoencefálica (BHE), en donde cada uno de dichos restos portadores está unido a un extremo C-terminal del anticuerpo de unión al objetivo. La presente invención se refiere además al uso de tales proteínas de suministro cerebral en la terapia o el diagnóstico, o para la investigación de, por ejemplo, trastornos neurodegenerativos, y otras enfermedades cerebrales.
MX2019000529A 2016-07-14 2017-07-13 Proteina de suministro cerebral. MX2019000529A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1651065 2016-07-14
PCT/EP2017/067727 WO2018011353A1 (en) 2016-07-14 2017-07-13 Brain delivery protein

Publications (1)

Publication Number Publication Date
MX2019000529A true MX2019000529A (es) 2020-01-15

Family

ID=59593007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000529A MX2019000529A (es) 2016-07-14 2017-07-13 Proteina de suministro cerebral.

Country Status (15)

Country Link
US (1) US11498974B2 (es)
EP (1) EP3484918A1 (es)
JP (2) JP2019529345A (es)
KR (1) KR20190039696A (es)
CN (1) CN109476728A (es)
AU (1) AU2017297804A1 (es)
BR (1) BR112019000098A2 (es)
CA (1) CA3028035A1 (es)
IL (1) IL263773A (es)
MA (1) MA45684A (es)
MX (1) MX2019000529A (es)
PH (1) PH12018502451A1 (es)
RU (1) RU2019102746A (es)
SG (2) SG10201912842VA (es)
WO (1) WO2018011353A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019009117A (es) 2017-02-17 2019-09-13 Bristol Myers Squibb Co Anticuerpos anti alfa-sinucleina y usos de los mismos.
KR20190129868A (ko) 2017-02-17 2019-11-20 데날리 테라퓨틱스 인크. 조작된 트란스페린 수용체 결합 폴리펩티드
EP3877399A4 (en) * 2018-11-06 2022-10-19 Alsatech, Inc. CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
MX2023014590A (es) 2021-06-11 2023-12-15 Bioarctic Ab Molecula de union biespecifica.
WO2023215697A1 (en) * 2022-05-05 2023-11-09 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
WO2024080843A1 (ko) * 2022-10-14 2024-04-18 주식회사 아임뉴런 뇌혈관장벽 투과성 융합 단백질 및 이의 용도
KR20240087579A (ko) * 2022-12-08 2024-06-19 주식회사 아델 항-타우 항체 및 펩티드를 포함하는 융합체와 그의 용도
WO2024200267A1 (en) 2023-03-24 2024-10-03 Bioarctic Ab Bispecific antibody binding to the protease-like domain of the human transferrin receptor htfr1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1309341A2 (en) 2000-07-07 2003-05-14 Lars Lannfelt Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2630344C (en) 2006-03-23 2015-04-28 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
AU2007285763B2 (en) * 2006-08-18 2011-12-15 Armagen Technologies, Inc. Agents for blood-brain barrier delivery
SI2276485T1 (sl) 2008-04-24 2014-10-30 Bristol-Myers Squibb Company Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo
PL2282758T3 (pl) 2008-04-29 2019-04-30 Bioarctic Ab Przeciwciała i szczepionki do zastosowania w terapeutycznych i diagnostycznych sposobach dla zaburzeń związanych z alfa-synukleiną
US8697074B2 (en) 2008-07-10 2014-04-15 Esbatech, An Alcon Biomedical Research Unit Llc Methods and compositions for enhanced delivery of macromolecules
WO2011001366A1 (en) 2009-06-29 2011-01-06 Bioartic Neuroscience Ab N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease
HUE038313T2 (hu) 2010-02-26 2018-10-29 Bioarctic Neuroscience Ab Protofibril-kötõ antitestek és alkalmazásuk Parkinson-kór, Lewy-testes demencia és más alfa-szinukleinopátiák terápiás és diagnosztikai eljárásaiban
BR112012032185A2 (pt) 2010-06-17 2016-10-11 Trellis Bioscience Inc anticorpos úteis na imunização passiva de influenza.
TWI689314B (zh) 2010-11-30 2020-04-01 建南德克公司 低親和力血腦障壁受體抗體及其用途
PT2890712T (pt) 2012-08-29 2019-06-28 Hoffmann La Roche Transportador para a barreira hematoencefálica
KR102362630B1 (ko) * 2013-08-26 2022-02-15 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
EP3129051A1 (en) * 2014-04-08 2017-02-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
MA40224B1 (fr) 2014-07-10 2021-05-31 Eisai R&D Man Co Ltd Anticorps se liant aux protofibrilles ass améliorés

Also Published As

Publication number Publication date
CA3028035A1 (en) 2018-01-18
MA45684A (fr) 2019-05-22
SG11201810801QA (en) 2019-01-30
RU2019102746A (ru) 2020-08-14
JP2022130646A (ja) 2022-09-06
EP3484918A1 (en) 2019-05-22
CN109476728A (zh) 2019-03-15
IL263773A (en) 2019-02-28
RU2019102746A3 (es) 2020-11-30
WO2018011353A1 (en) 2018-01-18
KR20190039696A (ko) 2019-04-15
BR112019000098A2 (pt) 2019-04-09
US20190225699A1 (en) 2019-07-25
PH12018502451A1 (en) 2019-09-30
SG10201912842VA (en) 2020-02-27
JP2019529345A (ja) 2019-10-17
AU2017297804A1 (en) 2019-01-24
US11498974B2 (en) 2022-11-15

Similar Documents

Publication Publication Date Title
PH12018502451A1 (en) Brain delivery protein
PH12020550205A1 (en) IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
WO2015031673A3 (en) Cns-targetedconjugates of antibodies
BR112018010084A2 (pt) ligantes de pd1 e/ou lag3
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
DOP2018000125A (es) Proteínas de unión a ctla4p
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
MX2016011580A (es) Dominios de fibronectina tipo iii que se unen a albumina de suero.
MY194669A (en) Binding Proteins and Methods of use Thereof
EP4406612A3 (en) Anti-cd70 antibody drug conjugates
PE20171336A1 (es) Anticuerpos contra tau y sus usos
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
PH12014501083A1 (en) Anticancer fusion protein
EA201400568A1 (ru) Альбуминсвязывающие антитела и их связывающие фрагменты
MD3665192T2 (ro) Polipeptide de legare a receptorului de transferrină modificate genetic
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
PH12014501363A1 (en) Anticancer fusion protein
MX2013007872A (es) Proteina de fusion anticancer.
MX366178B (es) Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos.
MX2017014397A (es) Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn).
AU2018249796A1 (en) Antibody Fc variants for improving blood half-life
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
WO2015112895A3 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
PL394618A1 (pl) Przeciwnowotworowe bialko fuzyjne